Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1S | Q13698 | 9/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.83 |
| ▸ | TSHR | P16473 | 2/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.83 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.83 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.83 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.83 |
| ▸ | HRH2 | P25021 | 1/20 | 0.83 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.83 |
| ▸ | SCN1A | P35498 | 1/20 | 0.83 |
| ▸ | SCN4A | P35499 | 1/20 | 0.83 |
| ▸ | HTT | P42858 | 1/20 | 0.83 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.83 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.83 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.83 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.83 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.83 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Siratiazem SCHEMBL9229070 | 1.00 | CACNA1S (0.83) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Siratiazem SCHEMBL9226375 | 0.99 | CACNA1S (0.82) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| SCHEMBL9838284 | 0.92 | CACNA1S (0.82) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| SCHEMBL12557669 | 0.91 | CACNA1S (0.69) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL4886734 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL3468378 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL30127157 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL614334 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL29353951 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL676914 | 0.91 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-04-17 | — | — | US | claimed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220047505-A1 | Controlled Absorption Water-Soluble Pharmaceutically Active Organic Compound Formulation for Once-Daily Administration | STI PHARMA, LLC (US) | 2022-02-17 | — | — | US | disclosed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | disclosed |
| US-11191719-B2 | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration | STI PHARMA, LLC (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-02-04 | — | — | US | disclosed |
| US-7101909-B2 | Compound of a ligand of 2-methoxy methylester-6-fluoronaphthalene, an aryl ligand and a linker; each ligand domain capable of binding to a Ca++ channel | THERAVANCE, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PHARMACIA CORPORATION | 2006-06-22 | — | — | US | disclosed |
| CN-1780823-A | Heteroaromatic pentacyclic compound and medicinal use thereof | JAPAN TOBACCO INC (JP) | 2006-05-31 | — | — | CN | disclosed |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2005-07-21 | — | — | US | disclosed |
| US-6897305-B2 | Calcium channel drugs and uses | THERAVANCE, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040242561-A1 | Novel calcium channel drugs and uses | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-02 | — | — | US | disclosed |
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | THERAVANCE BIOPHARMA R&D IP, LLC | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030695-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | CACNA1S 11/4885CYP3A4 4501/4885TSHR 4201/4885 |
| US-20030073127-A1 | NOVEL CALCIUM CHANNEL DRUGS AND USES | CACNB2, CACNA1B, CACNA1F | CACNA1S 17/4885CYP3A4 2951/4885TSHR 4227/4885 |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | CACNA1S 70/4885CYP3A4 4368/4885TSHR 2439/4885 |
| US-20060135506-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders | PTGS2, PTGES2, PTGS1 | CACNA1S 145/4885CYP3A4 2436/4885TSHR 4669/4885 |
| US-20040242561-A1 | Novel calcium channel drugs and uses | CACNB2, CACNA1B, CACNA1F | CACNA1S 17/4885CYP3A4 2951/4885TSHR 4227/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | CACNA1S 11/4885CYP3A4 4501/4885TSHR 4201/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | CACNA1S 9/4885CYP3A4 4504/4885TSHR 4135/4885 |
| US-20050159403-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage | PTGS2, PTGS1, PTGIS | CACNA1S 52/4885CYP3A4 3681/4885TSHR 4570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.